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Abstract
OBJECTIVES: This randomised, double-blind, placebo-controlled phase IIIb
study evaluated the impact of abatacept on MRI pathology as a primary outcome
in methotrexate (MTX)-refractory patients with rheumatoid arthritis. METHODS:
Patients received intravenous abatacept (∼10 mg/kg) or placebo, on background
MTX, for 4 months, followed by an 8-month open-label extension (OLE; all
patients received abatacept plus MTX). Patients had 1.5T MRI with intravenous
contrast at baseline, Months 4 and 12; wrist synovitis (three locations assessed),
and wrist and hand (15 and eight locations assessed, respectively) osteitis and
erosion were scored using OMERACT-RAMRIS. RESULTS: 26/27 abatacept-
and 23/23 placebo-randomised patients completed Month 4 and entered the OLE;
26 and 21 completed Month 12. The primary endpoint was not achieved; mean
change (SD) from baseline in synovitis was -0.44 (1.47) for abatacept versus 0.52
(1.38) for placebo (p=0.103) at Month 4. For mean change in synovitis adju...
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ABSTRACT
Objectives This randomised, double-blind, placebo-
controlled phase IIIb study evaluated the impact of
abatacept on MRI pathology as a primary outcome in
methotrexate (MTX)-refractory patients with rheumatoid
arthritis.
Methods Patients received intravenous abatacept
(∼10 mg/kg) or placebo, on background MTX, for
4 months, followed by an 8-month open-label extension
(OLE; all patients received abatacept plus MTX). Patients
had 1.5T MRI with intravenous contrast at baseline,
Months 4 and 12; wrist synovitis (three locations
assessed), and wrist and hand (15 and eight locations
assessed, respectively) osteitis and erosion were scored
using OMERACT-RAMRIS.
Results 26/27 abatacept- and 23/23 placebo-
randomised patients completed Month 4 and entered the
OLE; 26 and 21 completed Month 12. The primary
endpoint was not achieved; mean change (SD) from
baseline in synovitis was −0.44 (1.47) for abatacept
versus 0.52 (1.38) for placebo (p=0.103) at Month 4.
For mean change in synovitis adjusted for baseline score
(sensitivity analysis), the difference between groups was
−0.69, p=0.078. Adjusted mean changes (SE) in osteitis
and erosion were −1.94 (0.86) and 0.45 (0.43) for
abatacept, and 1.54 (0.90) and 0.95 (0.45) for placebo.
Further MRI improvements were observed up to Month 12
for abatacept and from Months 4 to 12 for placebo-treated
patients switched to abatacept at Month 4. Clinical
efﬁcacy was shown with abatacept and sustained to
Month 12.
Conclusions Despite small patient numbers, MRI
detected structural and synovial beneﬁt, sustained to
Month 12 in abatacept+MTX-treated patients, and
improvements in structural and inﬂammatory outcomes for
placebo+MTX-treated patients following addition of
abatacept.
Clinical trial registration Clinicaltrials.gov
NCT00420199.
INTRODUCTION
Evidence of joint destruction and bone loss in
rheumatoid arthritis (RA)1–4 has created the need
for reliable tools to accurately control the inﬂam-
matory process. MRI visualises bone damage (ero-
sions) with increased sensitivity over conventional
radiography and enables detection of synovial
inﬂammation (synovitis) and bone oedema (oste-
itis).1 2 5 While early MRI studies used longitudinal
observational cohorts to assess disease progression
and therapeutic response,5 relatively few rando-
mised controlled trials (RCTs) have included this
technique as a key outcome.3 4 6–11
In clinical trials with intravenous abatacept—a
fully human, recombinant fusion protein select-
ively modulating the CD80/CD86:CD28 costimu-
latory signal for full T cell activation—inhibition
of radiographic damage progression was sustained
over 5 years in patients with established RA, with
an increasing inhibitory effect seen over 2 years in
patients with early disease.12–17 The present
exploratory ASSET (Impact of Intravenous
Abatacept on Synovitis, Osteitis and Structural
DamagE in Patients with Rheumatoid Arthritis
and an Inadequate Response to Methotrexate
(MTX): A Randomised Controlled Trial) study
aimed to evaluate the effect of abatacept versus
placebo on MRI pathology and clinical efﬁcacy and
safety.
METHODS
Study design
ASSET was a phase IIIb randomised, double-blind
(DB), placebo-controlled study of 4 months dur-
ation with an 8-month open-label extension
(OLE), conducted at 11 medical centres in Europe
(May 2007–August 2009). Patients were rando-
mised 1 : 1 to receive abatacept (∼10 mg/kg accord-
ing to weight range) or placebo, plus background
MTX, for 4 months. Randomisation was by
central allocation of a unique number in order of
qualiﬁcation for treatment. Clinicians and patients
were blinded; drug preparation professionals were
unblinded.
Abatacept or placebo was administered intraven-
ously on Days 1, 15, 29 and every 28 days up to
and including Month 4. During the OLE all
patients received abatacept every 28 days from
Month 5 up to Month 12, plus background MTX.
Patients exited early if they missed >2 consecutive
doses; received high dose oral corticosteroids for
>2 weeks; or were insufﬁciently controlled (at
investigator discretion).
Open Access
Scan to access more
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The primary endpoint was the difference between groups in
mean change from baseline to Month 4 in wrist synovitis
score; changes in wrist and hand osteitis and erosion were sec-
ondary endpoints. The study (clinicaltrials.gov: NCT00420199)
was conducted in accordance with Good Clinical Practice, as
deﬁned by the International Conference on Harmonisation, and
the ethical principles of the Declaration of Helsinki.
Institutional review boards or independent ethics committees
approved the protocol, and signed, written informed consent
was provided by patients.
During the study, the following amendments to study design
occurred. Patients could have moderate or high, instead of high,
baseline disease activity, in order to improve the feasibility of
the study and reﬂect the improving standard of RA care, given
that MTX failure patients may not reach high disease activity
before receiving a biologic. The timeframe during which
intra-articular steroid injections were prohibited was reduced
from 12 to 3 months prior to screening (initial restriction
deemed too conservative).
Patient population
Patients (aged ≥18 years) had active RA (according to American
Rheumatism Association (1987) criteria) ≤5 years’ duration.
Active RA was deﬁned as either Disease Activity Score 28
(DAS28) based on C reactive protein (CRP) >3.2 or a tender
joint count of ≥6, a swollen joint count of ≥6 and a CRP meas-
urement greater than the upper limit of normal. Patients had
clinically detectable synovitis of at least the target wrist at
screening and Day 1 and, in addition, ≥1 erosion present in the
hands/wrists and/or feet (on previous radiographs) or were
anticyclic citrullinated peptide (CCP) or rheumatoid factor
(RF) positive. Patients had received MTX ≥15 mg/week or a
maximum tolerated dose (≥10 mg/week) for ≥3 months prior
to Day 1 (stable dose ≥28 days prior to ﬁrst study dose).
Concomitant medications
Permitted concomitant medications throughout the 12-month
study included stable dose MTX (10–25 mg/week; decreases
permitted for toxicity during DB) and a stable, low dose of oral
corticosteroids (reduced to equivalent ≤10 mg/day prednisolone
for 28 days). Intra-articular or intramuscular corticosteroid injec-
tions were not permitted from 3 months prior to Day 1. In the
OLE, one intramuscular, intra-articular or high dose oral cortico-
steroid course (deﬁned as >10 mg/day equivalent of prednisol-
one for ≥3 consecutive days) was allowed at the discretion of
the investigator until the clinical situation had resolved; no
intra-articular injections were permitted for the last month of
the OLE.
MRI assessments
Patients had 1.5 Tesla MRI, T1W–coronal short-τ inversion
recovery (469×625×3000 mm voxels) and fat-suppressed 3D
gradient-echo (234×625×1500 mm voxels) of one hand and
wrist (based on clinical involvement) and fat-suppressed 3D
gradient-echo plus intravenous gadolinium contrast of the same
wrist—at baseline (Day 1), Month 4 (Day 113) and Month 12
(Day 337). A single expert radiologist, blinded to both treat-
ment assignment and time order, scored all images for syno-
vitis, osteitis and bone erosion according to the OMERACT
rheumatoid arthritis MRI score (RAMRIS) method.18 Images
were checked for technical quality and read by a central facility.
Two MRI readings were independently made: (1) baseline and
Month 4 timepoints (prespeciﬁed analysis of the DB period)
and (2) baseline, Month 4 and Month 12 timepoints (OLE
analysis). The baseline and Month 4 MRIs were reread at the
second reading to maintain reader blinding to timepoint order.
Intraclass correlation coefﬁcients for the two readings were
0.87 (synovitis), 0.98 (osteitis) and 0.94 (erosion) for baseline
MRI scores; 0.89 (synovitis), 0.96 (osteitis) and 0.94 (erosion)
for Month 4 MRI scores; and 0.70 (synovitis), 0.86 (osteitis)
and 0.55 (erosion) for change from baseline to Month 4 MRI
scores.
The proportions of MRI non-progressors for synovitis, oste-
itis and erosion were evaluated, deﬁned as patients with MRI
score change <1 unit from baseline.19 For further details on the
joints that were assessed by MRI and how scoring was per-
formed, please see the online supplementary appendix.
Clinical efﬁcacy
Disease activity was assessed at each study visit until Month 6,
and then at Months 9 and 12 using DAS28 (composite of four
variables: 28 tender joint count, 28 swollen joint count, CRP
and patient assessment of disease activity (visual analogue
scale)) and Simpliﬁed Disease Activity Index (SDAI; CRP).
DAS28-deﬁned low disease activity state (LDAS: DAS28≤3.2)
and remission (DAS28<2.6), and SDAI-deﬁned LDAS
(SDAI≤11) and remission (SDAI≤3.3) were determined.
Safety
Adverse events (AEs), serious AEs and AEs of interest, including
infections, malignancies and prespeciﬁed acute infusional reac-
tions, were assessed in patients who received at least one dose
of abatacept. See online supplementary appendix for further
details.
Statistics
A total of 50 randomised patients yielded ≥87% power to
detect an improvement of 1.44 units in the primary endpoint
between the treatment arms using a non-parametric two-sided
Wilcoxon test at the 5% signiﬁcance level. Sample size calcula-
tion was based on three previous studies.20–22
For the primary endpoint, comparisons between groups in
mean change in wrist synovitis from baseline to Month 4
(based on ﬁrst reading of baseline and Month 4 MRIs) were
based on non-parametric analysis of covariance (ANCOVA),
with the rank score for change from baseline in total wrist
synovitis score as dependent variable, treatment group as main
effect and rank score for total wrist synovitis score at baseline
as additional covariate. The p value for the comparison, with
signiﬁcance level 0.05, was calculated. As probability plots did
not reveal deviations from normality in changes from baseline
in wrist synovitis score to Month 4, a post hoc sensitivity ana-
lysis of the primary endpoint was performed using a parametric
ANCOVA, allowing for estimation of the adjusted mean differ-
ence between treatment groups. In this sensitivity analysis,
change from baseline was the dependent variable, treatment
group was the main effect and baseline value an additional
covariate.
Adjusted mean changes in synovitis, osteitis and erosion
scores from baseline to Month 4, from baseline to Month 12,
and from Month 4 to Month 12 were calculated. Adjustment
was based on an ANCOVA model with treatment as factor and
baseline value as covariate; no between-group comparisons
were made. No formal statistical testing was applied to any of
the clinical efﬁcacy outcome analyses.
MRI scores and clinical efﬁcacy up to Month 4 are presented
for the modiﬁed intent-to-treat population, which included all
patients randomised and treated with data available at baseline
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and visit of interest (as-observed). Results up to Month 12
(OLE) are presented for patients treated in the OLE with data
available at baseline and visit of interest (as-observed).
RESULTS
Patient disposition and baseline demographics
Of 50 randomised and treated patients (abatacept (n=27) and
placebo (n=23)), one (abatacept group) discontinued the DB
period due to no longer meeting study criteria (hyperparathyr-
oidism). Of the 49 patients who entered the OLE, 47 (95.9%)
completed the study. Two patients, both originally randomised
to placebo, discontinued the OLE (see online supplementary
ﬁgure S1).
Baseline disease characteristics for patients randomised and
treated in the DB period were generally similar between groups,
although more patients in the placebo versus abatacept group
were RF or anti-CCP positive (table 1) and baseline synovitis and
erosion scores were higher in the abatacept group (ﬁgure 1A).
Concomitant medications and drug exposure
At randomisation, concomitant medications were comparable
between groups (table 1), and use remained relatively stable
throughout DB treatment. During the OLE, all patients contin-
ued to receive MTX; 18 (69.2%) and 15 (65.2%) patients in the
original abatacept group and the original placebo group,
respectively, received low dose corticosteroids (≤10 mg prednis-
olone equivalent: mean dose: 3.7 and 3.1 mg/day, respectively).
One patient received more than one course of high dose corti-
costeroids and one patient received more than two
intra-articular steroid injections (both original placebo group).
The mean (SD) total duration of abatacept exposure across the
DB and OLE was 13.2 (0.20) months in the original abatacept
group and 8.3 (0.84) months in the original placebo group
switched to abatacept at Month 4.
MRI assessments
Primary endpoint: Month 4 (ﬁrst reading)
Mean MRI scores at baseline and Month 4, according to the
ﬁrst MRI reading, are shown in ﬁgure 1A. From baseline to
Month 4, reduction in wrist synovitis score (primary endpoint)
was seen for the abatacept group (mean change (SD): −0.44
(1.47), n=25) compared with worsening of wrist synovitis for
the placebo group (mean change (SD): 0.52 (1.38), n=23), but
the difference between treatment groups was not signiﬁcant
(p=0.103).
Sensitivity analysis of primary endpoint: Month 4 (ﬁrst reading)
The sensitivity analysis adjusted for baseline synovitis score
using a parametric ANCOVA. In this analysis, mean change
(SE) in synovitis was −0.31 (0.26) for abatacept versus 0.38
(0.27) for placebo (ﬁgure 1A). Difference between treatment
groups in adjusted mean synovitis score change approached sig-
niﬁcance (−0.69 (95% CI −1.45 to 0.08); p=0.078).
Adjusted mean change in osteitis and erosion: Month 4 (ﬁrst reading)
A greater reduction in adjusted mean (SE) osteitis score from
baseline to Month 4 was observed in the abatacept (n=25)
versus placebo (n=23) group: −1.94 (0.86) versus 1.54 (0.90),
respectively (ﬁgure 1A). Erosion progression was also reduced in
the abatacept versus placebo group at Month 4 with adjusted
mean change (SE) from baseline in erosion scores of 0.45 (0.43)
versus 0.95 (0.45), respectively (ﬁgure 1A).
Month 4 (second reading) MRI outcomes
Data from the second MRI reading (baseline and Month 4 were
reread at Month 12; ﬁgure 1B–D, left-hand panels) were gener-
ally consistent with the MRI data from the ﬁrst reading.
MRI analysis: Month 12
In the original abatacept group, further improvements in wrist
synovitis and wrist and hand osteitis were seen from Months 4
to 12 (ﬁgure 1B,C; middle and right-hand panels). In the ori-
ginal placebo group, reductions in synovitis and osteitis were
seen after addition of abatacept at Month 4, and by Month 12
the changes from baseline in synovitis and osteitis were similar
to those seen in the original abatacept group. Reduced progres-
sion of erosion was seen in the original abatacept group from
Month 4 to Month 12 with continued treatment (ﬁgure 1D;
middle and right-hand panels). Erosion score was also reduced
in the original placebo group following addition of abatacept at
Month 4, although the extent of this reduction was not as
great as that seen in the original abatacept group by Month 12.
MRI non-progressors: Months 4 and 12
A higher proportion of patients in the abatacept group demon-
strated non-progression of synovitis and osteitis at Month 4
compared with the placebo group (ﬁgure 2; left-hand panels).
At Month 12, the proportions of MRI non-progressors for each
outcome in the original placebo group switched to abatacept
were generally similar to those in the original abatacept group
(ﬁgure 2; right-hand panels).
Table 1 Baseline demographic and clinical characteristics for
randomised and treated patients
Abatacept+MTX
(n=27)
Placebo+MTX
(n=23)
Age (years) 51.7±11.2 52.5±11.5
Female, n (%) 16 (59.3) 16 (69.6)
Caucasian, n (%) 26 (96.3) 19 (82.6)
Duration of RA (months) 25.7±18.0 28.2±17.0
Tender joints, n 12.9±7.1 13.3±7.2
Swollen joints, n 11.3±6.6 8.5±4.1
Patient global assessment, VAS
100 mm
50.9±24.7 56.6±24.4
Physician global assessment, VAS
100 mm
51.5±18.7 57.4±15.1
Positive RF status, n (%)* 15 (55.6) 19 (82.6)
Positive anti-CCP2 status, n (%)* 13 (48.1) 17 (73.9)
DAS28 (CRP) 5.3±1.1 5.3±0.9
CRP (mg/l) 13.6±17.4 16.6±16.8
CDAI 34.4±15.3 33.2±10.3
SDAI (CRP) 35.8±16.1 34.9±10.8
Concomitant medications at baseline, n (%)
MTX 23 (100) 27 (100)
MTX dose, mean±SD mg/week 16.9±4.6 17.3±4.2
Oral and/or injectable
corticosteroids
19 (70.4) 14 (60.9)
Low dose oral corticosteroids 16 (59.3) 12 (52.2)
Oral dose of corticosteroids, mean
±SD
3.9±3.51 3.0±3.72
NSAIDs 22 (81.5) 20 (87.0)
Values are means±SD unless stated otherwise.
*Per the inclusion criteria, if patients were not RF or anti-CCP2 positive, they had to
have radiographic evidence of erosion.
CCP, cyclic citrullinated protein; CDAI, Clinical Disease Activity Index; CRP, C
reactive protein; DAS28, Disease Activity Score 28; MTX, methotrexate; NSAIDs,
non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid
factor; SDAI, Simplified Disease Activity Index; VAS, visual analogue scale.
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Disease activity assessments
Mean reductions (95% CI) from baseline to Month 4 and
Month 12 in DAS28 (CRP) and SDAI are shown in online
supplementary ﬁgure S2. A higher proportion of patients from
the original abatacept group reached remission and LDAS
(DAS28- and SDAI-deﬁned) at Month 12 than at Month 4
(ﬁgure 3A). At Month 12, the proportion of patients reaching
remission and LDAS according to both DAS28 and SDAI cri-
teria remained greater in the original abatacept group than in
the original placebo group (ﬁgure 3).
A post hoc analysis examined the relationship between
disease activity at Month 4 and MRI scores at Month 12 in
patients treated in the OLE who were originally randomised to
abatacept (table 2). Greater reductions in erosion progression
and synovitis score at Month 12 were seen for patients with
lower versus higher disease activity at Month 4. Osteitis score at
Month 12 was reduced regardless of Month 4 disease activity.
Safety
A summary of AEs is reported in table 3 and in online
supplementary appendix. Most AEs were considered mild or
moderate in intensity, and none resulted in withdrawal.
DISCUSSION
In the phase IIIb, exploratory, ASSET study, intravenous abata-
cept plus MTX was associated with reductions in synovitis and
osteitis and less progression of erosion, compared with placebo
plus MTX; increased proportions of abatacept-treated patients
experienced non-progression of synovitis and osteitis after
4 months compared with patients receiving placebo plus MTX.
A persistent beneﬁcial effect on osteitis and synovitis was
observed in patients who remained on abatacept over
12 months, with inhibition of erosion progression also seen.
Following addition of abatacept, patients initially randomised
to placebo achieved incremental reductions in synovitis and
osteitis by Month 12 to levels similar to those seen in patients
who had continuously received abatacept. These patients also
showed reduced progression in erosion score after initiating
abatacept.
MRI assessment of abatacept-treated patients has previously
been reported in the ADJUST trial in MTX-naive patients with
very early or undifferentiated inﬂammatory arthritis, and in
patients with psoriatic arthritis.23 24 The improvements in
MRI synovitis, osteitis and erosion progression seen here with
abatacept plus MTX over 12 months are consistent with
Figure 1 (A) Mean baseline and Month 4 MRI scores based on the ﬁrst MRI reading and adjusted mean changes from baseline in (B) synovitis,
(C) osteitis and (D) erosion scores based on the second MRI reading. Treatment groups represent treatment received in the DB period. Data are
presented for all patients who had MRIs available at the visits of interest (as-observed analysis); for the analyses presented in A, data are based on
MRIs read at Month 4, and for the analyses presented in (B–D), data are based on MRIs read at Month 12 (baseline and Month 4 MRIs were reread
at this timepoint); patients with MRI outside of Days 92–134 were excluded from the Day 113 (Month 4) analysis, and with MRI >4 weeks prior to
or after Day 337 were excluded from the Month 12 MRI analysis. Adjustment (B–D) is based on ANCOVA model with treatment as factor and
baseline value as covariate. (B–D) Error bars represent 95% CI of the adjusted mean change. Synovitis was assessed only in the wrist (three
regions), whereas osteitis and erosion were assessed in the wrist and MCP joints (23 sites: 15 sites in wrist, plus eight in the hand). ANCOVA,
analysis of covariance; DB, double-blind; MCP, metacarpophalangeal; MTX, methotrexate.
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ﬁndings from those trials, and with pharmacodynamic data
that suggest abatacept may have a positive effect on bone
metabolism through its regulatory effect on osteoclast differen-
tiation and bone resorption.20 The degree of local baseline
inﬂammation, both synovitis and osteitis, predicts erosion pro-
gression during early disease.25–27 Consequently, improving
osteitis scores may favourably impact the long-term prognosis
of erosion progression. Indeed, inhibition of erosion progression
was seen over 12 months of abatacept plus MTX treatment for
patients in this study, but was not observed by Month 4.
The beneﬁcial MRI outcomes seen with abatacept are also
consistent with those reported for conventional disease-
Table 2 Post hoc analysis data
Mean change (95% CI) in score from baseline to
Month 12
DAS28
status at
Month 4 N
Synovitis
(wrist)
Osteitis
(wrist and hand)
Erosion
(wrist and hand)
Remission (<2.6)* 4 −3.00
(−6.90 to 0.90)
−2.75
(−8.47 to 2.97)
−4.75
(−13.11 to 3.61)
LDAS (≤3.2) 11 −2.64
(−4.15 to −1.13)
−4.09
(−8.44 to 0.26)
−2.18
(−5.12 to 0.85)
MDAS (>3.2–5.1) 9 −1.00
(−2.84 to 0.84)
−3.22
(−8.17 to 1.73)
1.56
(0.27 to 2.84)
HDAS (>5.1) 3 0.00
(0.00 to 0.00)
−1.33
(−5.13 to 2.46)
1.33
(−1.54 to 4.20)
Data are as observed for patients treated in the open-label extension who were
originally randomised to abatacept+MTX, who had data available at the visits of
interest.
*Subset of LDAS.
DAS28, Disease Activity Score 28; HDAS, high disease activity state; LDAS, low
disease activity state; MDAS, moderate disease activity state; MTX, methotrexate.
Figure 3 Patients achieving improvements in disease activity
according to (A) DAS28-derived criteria and (B) SDAI-derived criteria.
Treatment groups represent treatment received in the DB period. DB
data (Month 4) are based on the mITT population including all
randomised and treated patients with data available at the visits of
interest (as-observed analysis); OLE data (Month 12) are based on
patients treated in the OLE, with data available at the visit of interest.
Error bars represent 95% CI. CRP, C reactive protein; DAS28, Disease
Activity Score 28; DB, double-blind; LDAS, low disease activity state
(DAS28 (CRP) ≤3.2; SDAI≤11); mITT, modiﬁed intent to treat; MTX,
methotrexate; OLE, open-label extension; Remission (DAS28 (CRP)
<2.6; SDAI≤3.3); SDAI, Simpliﬁed Disease Activity Index.
Figure 2 MRI non-progressors at Month 4 and Month 12 in
(A) synovitis score, (B) osteitis score and (C) erosion score. Treatment
groups represent treatment received in the DB period. Data are
presented for all patients who had MRIs available at the visits of
interest (as-observed analysis); patients with MRI outside of Days
92–134 were excluded from the Day 113 (Month 4) analysis, and
with MRI >4 weeks prior to or after Day 337 were excluded from the
Month 12 MRI analysis. Non-progressors deﬁned by mean change from
baseline in MRI score <1 RAMRIS unit. Error bars represent 95% CI.
Synovitis was assessed only in the wrist, whereas osteitis and erosion
were assessed in the wrist and MCP joints. DB, double-blind; MCP,
metacarpophalangeal; MTX, methotrexate; RAMRIS, rheumatoid
arthritis MRI score.
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modifying antirheumatic drugs28 and other biologics, with
recent RCTs documenting the beneﬁcial effects on MRI assess-
ments of inﬂiximab, adalimumab and golimumab in patients
with early RA,4 7 10 21 and of denosumab,6 fostamatinib,8 toci-
lizumab,29 rituximab30 and golimumab3 in patients with estab-
lished disease. However, caution must be used when making
comparisons across these trials owing to general differences,
such as study design, patient populations (particularly different
stages of RA) and timepoints evaluated, and MRI-related differ-
ences, such as differing magnet ﬁeld strengths, pulse sequence
parameters, the use of contrast agents and the anatomical loca-
tions assessed (eg, metacarpophalangeal (MCP) joints and
wrists vs wrists alone, as in the current study).
Abatacept treatment improved disease activity over time in
this study, consistent with previous abatacept trials,15 31
although the proportion of patients achieving treatment targets
(based on DAS28 and SDAI) was higher in the current study,
probably because these patients had less severe disease at base-
line. Patients originally randomised to placebo who switched to
abatacept at Month 4 experienced improvements in disease
activity by Month 12 that approached those observed in
patients continuously treated with abatacept. However, the
proportions of patients achieving DAS28 LDAS and DAS28 and
SDAI remission at Month 12 suggest that although disease
activity improves when patients switch to abatacept, many of
them do not reach the low states of disease activity seen in
patients who are continuously treated with abatacept.
Control of disease status at Month 4 in the original abata-
cept group was associated with greater numerical improve-
ments in synovitis and erosion at Month 12. Reductions in
osteitis were seen regardless of the level of disease activity at
Month 4.32 The disconnect between osteitis and clinical efﬁ-
cacy, where osteitis improved in the context of persistent clin-
ical disease, may be due to the regulatory effect of abatacept on
bone, discussed above, or the presence of subclinical disease.
Consequently, the reported positive effect on osteitis may
result in better long-term structural prognosis regardless of
initial clinical efﬁcacy outcomes.
Abatacept was well tolerated by patients, with a high reten-
tion rate in both the DB period and OLE. No new safety
signals were identiﬁed in the OLE relative to the DB period,
and overall safety was consistent with previous reports of
abatacept.15 31 33 34
Certain limitations of this study need to be taken into
account. Guidance for powering MRI studies remains uncer-
tain, including the number of anatomical sites to be evaluated11
and the responsiveness of the scoring system for each patho-
logical feature. This is a direct result of the paucity of published
MRI RCTs at the time the study was designed. Therefore,
extrapolation of data from previous MRI RCTs to determine
the sample size and anatomical sites may have been imprecise
and, as such, this study should be considered exploratory.
Assessment of synovitis in this study was restricted to the
wrist; contrast-enhanced images of the MCP joints were not
acquired owing to limitations in MRI examination time.
Additionally, osteitis and erosion were not assessed at MCP 1,
as per recent modiﬁcation of RAMRIS.6 18 Another limitation
is that the MRI images were read and scored by only one
reader; it has been demonstrated that averaging scores from
additional readers can reduce error.11 Had two MRI readers
been used, and a greater number of patients included in the
study, the ﬁndings for the primary and secondary outcomes
may have been different. Finally, the limited number of patients
included in this study, and the difference in proportions of RF
and anti-CCP positive patients between groups, should also be
taken into account when interpreting the analyses. While small
MRI studies are suitable for exploring mechanisms of action,
the limited number of patients leads to difﬁculties in interpret-
ing the relationship between a small number of MRI assessed
sites and systemic assessment of disease activity.
Even with the wrist-only assessments of synovitis, abatacept
plus MTX was associated with reductions in osteitis, minimal
deterioration in erosion and a trend toward reduced MRI syno-
vitis versus placebo plus MTX over 4 months, demonstrating
an early effect of abatacept on inﬂammation and structural
damage. With continued treatment, patients initially rando-
mised to abatacept experienced persistent beneﬁt in synovitis
and osteitis, with inhibition of erosion progression; patients ini-
tially randomised to placebo achieved incremental reductions in
MRI assessed inﬂammation and slowing of erosion progression
after switching to abatacept. In conclusion, data from the
ASSET study extend current knowledge on the early effect of
intravenous abatacept on synovium and bone and conﬁrm its
use as an effective and well-tolerated therapeutic option in
patients with RAwho have previously failed MTX therapy.
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Table 3 Summary of adverse events during the study
DB period* OLE†
Adverse events, number
of patients (%)
Abatacept+MTX
(n=27)
Placebo+MTX
(n=23)
Abatacept+MTX
(n=49)
Adverse events 20 (74.1) 14 (60.9) 41 (83.7)
Related adverse events 8 (29.6) 6 (26.1) 24 (49.0)
Serious adverse events 0 2 (8.7) 6 (12.2)
Infections 10 (37.0) 6 (26.1) 26 (53.1)
Serious infections 0 0 1 (2.0)
Malignancies 0 0 0
Autoimmune events 0 0 1 (2.0)
Acute infusion events 0 4 (17.4) 2 (4.1)
Peri-infusional events 4 (14.8) 5 (21.7) 6 (12.2)
Deaths 0 0 0
*Includes data up to 56 days post the last study drug dose for patients who
discontinued or up to the first dose of the OLE for patients who continued.
†Events for all patients who received at least one dose of abatacept in the 8-month
OLE, up to 56 days post the last dose of open-label abatacept.
DB, double-blind; MTX, methotrexate; OLE, open-label extension.
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